Alpha-synuclein and Parkinson's Disease
What is alpha-synuclein?
Alpha-synuclein (also α-synuclein) is a protein whose function in the healthy brain is currently unknown. It is of great interest to Parkinson's researchers because it is a major constituent of Lewy bodies, protein clumps that are the pathological hallmark of Parkinsonís disease.
In the several years since its discovery, alpha-synuclein has been the focus of intensive efforts by basic Parkinsonís disease researchers working to definitively characterize the protein's role in Parkinsonís and its potential as a target for neuroprotective therapies. Despite this, there are still more questions than answers as to whether and how alpha-synuclein plays a direct causative role in Parkinsonís disease.
What is alpha-synuclein?
What is the latest research into the role that alpha-synuclein plays in Parkinsonís disease?
There is compelling evidence from recent studies that alpha-synuclein may play a role in the development of both (rare) familial and (more common) sporadic cases of Parkinson's disease.
For a very small subset of Parkinson's patients, hereditary variability in the alpha-synuclein gene contributes to developing the disease. In these rare cases of familial Parkinsonís disease, the alpha-synuclein gene produces either too much alpha-synuclein protein or an abnormal form of the protein ó unusual events believed by some researchers to be toxic to brain cells and to result in neuron dysfunction.
Furthermore, alpha-synuclein is the primary structural component of Lewy bodies, suggesting that protein aggregation plays a role in sporadic Parkinson's disease as well.
These findings support the development of Parkinsonís disease therapies that reduce alpha-synuclein gene expression or block its aggregation. Such therapies could potentially prevent or delay the onset of Parkinson's disease, or halt or slow its progression.
What's more, alpha-synuclein pathology has been found to exist in some body systems not traditionally associated with Parkinson's disease, as well as in patients who did not experience any clinical features of Parkinson's. For this reason, study of alpha-synuclein is crucial to test the emerging hypothesis that Parkinson's disease affects many areas of the central nervous system beyond the substantia nigra, and even extends beyond the boundaries of the central nervous system. This hypothesis has gained attention in recent years as appreciation has grown for the diversity of the clinical features of Parkinson's disease.
Finally, research is ongoing to determine whether alpha-synuclein may have a potential use as a biomarker of Parkinsonís disease.
What attempts have been made to develop an alpha-synuclein therapy
A vaccine approach targeting alpha-synuclein in Parkinsonís patients is now in the clinic.† The vaccine candidate, from Austrian biotech AFFiRiS, works by binding to alpha-synuclein and subsequently clearing it from the brain. It is now in the first stages of clinical testing.
Other approved compounds that have been shown to stop synuclein clumping, and to break up existing clumps, are moving forward in pre-clinical testing.
As of January 2012, The Michael J. Fox Foundation had invested over $47 million in projects targeting alpha-synuclein.
Fox Trial Finder
All clinical trials need participants.
Fox Trial Finder knows which trials need you.
Hear the Latest in PD Research
The MJFF Parkinson's Podcast Series pairs host Dave Iverson with Parkinson's researchers to talk about the latest scientific understanding and therapies in development.